Development of monolayer elementary osmotic tablet of verapamil hydrochoride
The purpose of this study was to develop a monolayer elementary osmotic tablet of Verapamil Hydrochloride. The drug candidate selected under the study is Verapamil hydrochloride, a calcium channel blocking agent used in the treatment of angina pectoris, hypertension and cardiac arrhythmia. Verapamil Hydrochloride has a short elimination half-life; this will bring down its dosing frequency to once a day and on the same time make a zero order release system. Tablets were prepared by using controlled release polymers. The formulations were evaluated for pharmacopoeial quality control tests and all the physical parameters evaluated were within the acceptable limits. Formulation M12 was proved to be good drug content, dimensional stability and drug release up to 24 h as compared to the other formulations. Stability studies were carried out on the optimized formulation M12 for period of 3 months at 400c/75 %RH. Finally it was observed that there was no change in physiochemical and physical properties as well as in drug release profile even after storage at 45 °C and 75 % for three months.
Full Text Attachment